Skip to main content

Table 3 Incidence of adverse events reported in the artesunate-amodiaquine treatment arm according to CYP2C8 genotype

From: Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar

 

*1/*1

*2 carriers

*3 carriers

Adverse events; % (n)

28.1 (55)

45.9 (50)

38.9 (7)

No adverse events; % (n)

71.9 (141)

54.1 (59)

61.1 (11)

Total; % (n)

100 (196)

100 (109)

100 (18)

  1. Out of the 329 subjects analysed for CYP2C8, 6 had incomplete data regarding adverse events and were therefore excluded from these calculations